Skip to main content
Graphic of a heart with a plus sign inside

Mirvetuximab soravtansine-gynx (ELAHERE®) is recommended by the National Comprehensive Cancer Network® (NCCN®) as the only Category 1, Preferred option for FRα-positive (≥75% positive tumor cells) platinum-resistant ovarian cancer1,2

Not indicated for pediatric patients. Patient portrayal.

ELAHERE is the first and only treatment to show superior efficacy vs standard single-agent chemotherapy in FRα-positive,* platinum-resistant ovarian cancer3-5†

Median PFS: 5.6 months (n=227; 95% CI: 4.3, 5.9) with ELAHERE vs 4.0 months (n=226; 95% CI: 2.9, 4.5) with standard chemotherapy, P<0.0001 (primary endpoint)3,4‡

Median OS: 16.5 months (n=227; 95% CI: 14.5, 24.6) with ELAHERE vs 12.7 months (n=226; 95% CI: 10.9, 14.4) with standard chemotherapy, P=0.0046 (key secondary endpoint)3,4§

ORR: 42% (n=225; 95% CI: 36, 49) with ELAHERE vs 16% (n=224; 95% CI: 12, 22) with standard chemotherapy, P<0.0001 (key secondary endpoint)3,4

*FRα positive is defined as ≥75% of viable tumor cells with moderate (2+) and/or strong (3+) membrane staining based on an IHC assay.2

†MIRASOL was a confirmatory, global, multicenter, randomized, open-label study evaluating the efficacy and safety of ELAHERE vs investigator's choice chemotherapy in FRα-positive, platinum-resistant ovarian cancer; ELAHERE (n=227) vs standard single-agent chemotherapy (n=226; paclitaxel, pegylated liposomal doxorubicin, or topotecan).3,4

‡HR: 0.65 (95% CI: 0.52, 0.81).3

§HR: 0.67 (95% CI: 0.50, 0.88).3
CI=confidence interval; FRα=folate receptor alpha; HR=hazard ratio; IHC=immunohistochemistry; ORR=overall response rate; OS=overall survival; PFS=progression-free survival.

EXPLORE CONFIRMATORY DATA

Not indicated for pediatric patients. Patient portrayal.

Looking for dosing information?

Find out how to calculate AIBW, see preparation and administration instructions, and review dose modifications.

LEARN ABOUT DOSING

Resources for you and your patients

Discover HCP-led videos, resources for access and reimbursement, information on eye care management, and more.

EXPLORE RESOURCES

Educational videos for you

Learn more from fellow HCPs about clinical data, the role of FRα, and treating patients with ELAHERE.

EXPLORE VIDEOS

AIBW=adjusted ideal body weight; HCP=healthcare professional.

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 23, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. Package insert. Roche; 2022.
  3. ELAHERE. Package insert. AbbVie; 2024.
  4. Moore KN, Angelergues A, Konecny GE, et al. N Engl J Med. 2023;389(23):2162-2174. doi:10.1056/NEJMoa2309169
  5. Matulonis UA, Lorusso D, Oaknin A, et al. J Clin Oncol. 2023;41(13):2436-2445. doi:10.1200/JCO.22.01900